Incyte Corporation (BVMF:I1NC34)

Market Cap	127.28B +30.3%
Revenue (ttm)	31.14B +24.9%
Net Income	2.09B -66.1%
EPS	5.20 -67.1%
Shares Out	n/a
PE Ratio	60.76
Forward PE	14.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177
Open	315.88
Previous Close	309.30
Day's Range	315.88 - 315.88
52-Week Range	232.56 - 328.68
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 2,844
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: I1NC34

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 29, 2026

Data Sources Report a data error